PL3082831T3 - Kompozycje oparte na metylocyklodekstrynach do leczenia i/lub zapobiegania chorobom poprzez podwyższenie poziomu cholesterolu HDL - Google Patents

Kompozycje oparte na metylocyklodekstrynach do leczenia i/lub zapobiegania chorobom poprzez podwyższenie poziomu cholesterolu HDL

Info

Publication number
PL3082831T3
PL3082831T3 PL14827505T PL14827505T PL3082831T3 PL 3082831 T3 PL3082831 T3 PL 3082831T3 PL 14827505 T PL14827505 T PL 14827505T PL 14827505 T PL14827505 T PL 14827505T PL 3082831 T3 PL3082831 T3 PL 3082831T3
Authority
PL
Poland
Prior art keywords
cyclodextrines
hdl
enhancement
treat
compositions
Prior art date
Application number
PL14827505T
Other languages
English (en)
Inventor
Marc Salome
Daniel Wils
Xavier Parissaux
François MACH
Fabrizio MONTECUCCO
Original Assignee
Roquette Frères
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roquette Frères filed Critical Roquette Frères
Publication of PL3082831T3 publication Critical patent/PL3082831T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL14827505T 2013-12-13 2014-12-12 Kompozycje oparte na metylocyklodekstrynach do leczenia i/lub zapobiegania chorobom poprzez podwyższenie poziomu cholesterolu HDL PL3082831T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1362633A FR3014694B1 (fr) 2013-12-13 2013-12-13 Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
PCT/FR2014/053309 WO2015087016A1 (fr) 2013-12-13 2014-12-12 Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
EP14827505.0A EP3082831B1 (fr) 2013-12-13 2014-12-12 Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl

Publications (1)

Publication Number Publication Date
PL3082831T3 true PL3082831T3 (pl) 2021-06-28

Family

ID=50424476

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14827505T PL3082831T3 (pl) 2013-12-13 2014-12-12 Kompozycje oparte na metylocyklodekstrynach do leczenia i/lub zapobiegania chorobom poprzez podwyższenie poziomu cholesterolu HDL

Country Status (15)

Country Link
US (2) US10022392B2 (pl)
EP (2) EP3581188A1 (pl)
JP (2) JP6322289B2 (pl)
KR (3) KR20160088874A (pl)
CN (2) CN110123831A (pl)
AU (2) AU2014363270B2 (pl)
BR (1) BR112016013481A2 (pl)
CA (2) CA2930489C (pl)
DK (1) DK3082831T3 (pl)
ES (1) ES2859609T3 (pl)
FR (1) FR3014694B1 (pl)
MX (2) MX381039B (pl)
PL (1) PL3082831T3 (pl)
RU (1) RU2677889C1 (pl)
WO (2) WO2015087017A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2880880C (en) 2012-08-03 2021-01-26 John Mckew Cyclodextrin for the treatment of lysosomal storage diseases
AU2016276774A1 (en) 2015-06-10 2018-01-18 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
FR3042501B1 (fr) * 2015-10-16 2017-11-03 Roquette Freres Nouvelles cyclodextrines methylees et leurs procedes de preparation
EP3432880A4 (en) * 2016-03-20 2019-12-11 Asdera LLC USE OF CYCLODEXTRINS TO REDUCE ENDOCYTOSIS IN MALIGNES AND NEURODEEGENERATIVE DISEASES
MX2019000342A (es) * 2016-07-08 2019-09-04 Ranedis Pharmaceuticals Llc Composiciones y metodos para tratar y/o prevenir enfermedades de almacenamiento lisosomal y otras enfermedades metabolicas monogeneticas.
KR101906578B1 (ko) * 2017-07-28 2018-10-10 경북대학교 산학협력단 사이클로덱스트린 및 vegf 과발현 줄기세포를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물
JP2020535235A (ja) 2017-09-28 2020-12-03 アスデラ エルエルシー リン脂質の調節異常が関与する疾患および障害におけるシクロデキストリンの使用
CN107982546A (zh) * 2017-12-05 2018-05-04 中国药科大学 基于主客体相互作用的酸敏感超分子纳米粒及其应用
US12089930B2 (en) 2018-03-05 2024-09-17 Marquette University Method and apparatus for non-invasive hemoglobin level prediction
CN108342473A (zh) * 2018-04-13 2018-07-31 东华大学 一种用于检测血脂代谢相关基因abcg1甲基化的试剂盒
US12522670B2 (en) 2018-06-29 2026-01-13 Roquette Freres Hydroxypropyl-beta-cyclodextrin and process for the production thereof
FR3083234B1 (fr) * 2018-06-29 2020-11-27 Roquette Freres Nouvelles hydroxypropyl-beta-cyclodextrines et leurs procedes de preparation
EP3873604B1 (en) * 2018-10-29 2024-08-21 Cyclo Therapeutics, Inc. Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin
AU2020204925B2 (en) 2019-01-03 2025-11-20 Cyclarity Therapeutics, Inc. Cyclodextrin dimers, compositions thereof, and uses thereof
US11446325B2 (en) * 2020-09-30 2022-09-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases
FR3115682B1 (fr) * 2020-11-05 2023-02-24 Roquette Freres Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique
JP2025506676A (ja) 2022-02-18 2025-03-13 ベレン セラピューティクス ピー.ビー.シー. ヒドロキシプロピル-ベータ-シクロデキストリンの組成物及びその精製方法
CN118715017A (zh) * 2022-02-18 2024-09-27 贝伦治疗公益公司 用2-羟基丙基-β-环糊精治疗高甘油三酯血症

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265230A (ja) * 1986-05-12 1987-11-18 Kao Corp 高脂血症治療・予防剤
BE1006873A6 (nl) * 1993-03-26 1995-01-10 Merkus Franciscus W H M Toedieningsformulering voor nasale insuline toediening.
WO1999038498A1 (en) 1998-01-28 1999-08-05 Warner-Lambert Company Method for treating alzheimer's disease
DE60032388T2 (de) 1999-11-12 2008-01-10 Frères Roquette Kristalline mischungen aus teilmethylethern des beta-cyclodextrins und verwandten verbindungen
AU2001253727A1 (en) * 2000-04-21 2001-11-07 The Trustees Of Columbia University In The City Of New York Methods for identifying compounds useful for preventing acute clinical vascular events in a subject
AUPR178300A0 (en) * 2000-11-29 2000-12-21 Heart Research Institute Ltd., The Cyclodextrins and reversal of atherosclerosis
TW200307011A (en) * 2002-04-18 2003-12-01 Chugai Pharmaceutical Co Ltd Hyaluronic acid modifier
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
AU2005272578A1 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid and hyluronidase inhibitors
GB0421176D0 (en) * 2004-09-23 2004-10-27 Poston Robin Treatment of atherosclerosis
US9034846B2 (en) * 2004-10-10 2015-05-19 Universite De Liege Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases
EP1655034A1 (en) 2004-10-10 2006-05-10 Université de Liège Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases.
US7879821B2 (en) * 2006-01-26 2011-02-01 University Of Medicine And Dentistry Of New Jersey Method for modulating inflammatory responses by altering plasma lipid levels
TW201006463A (en) * 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives

Also Published As

Publication number Publication date
AU2020200500A1 (en) 2020-02-13
EP3082831A1 (fr) 2016-10-26
CN110123831A (zh) 2019-08-16
WO2015087017A1 (fr) 2015-06-18
EP3581188A1 (fr) 2019-12-18
KR102463677B1 (ko) 2022-11-07
KR20210072129A (ko) 2021-06-16
JP2017500310A (ja) 2017-01-05
JP6322289B2 (ja) 2018-05-09
MX381039B (es) 2025-03-12
MX2016007658A (es) 2016-09-26
CN105792833A (zh) 2016-07-20
ES2859609T3 (es) 2021-10-04
AU2014363270A1 (en) 2016-05-19
CA3180528A1 (fr) 2015-06-18
WO2015087016A1 (fr) 2015-06-18
US20160361344A1 (en) 2016-12-15
MX388947B (es) 2025-03-19
US10022392B2 (en) 2018-07-17
KR102453643B1 (ko) 2022-10-12
AU2014363270B2 (en) 2020-03-12
CN105792833B (zh) 2021-06-25
DK3082831T3 (da) 2021-04-12
JP2018123153A (ja) 2018-08-09
AU2020200500B2 (en) 2021-08-12
FR3014694A1 (fr) 2015-06-19
CA2930489A1 (fr) 2015-06-18
RU2677889C1 (ru) 2019-01-22
KR20210158867A (ko) 2021-12-31
US20180207198A1 (en) 2018-07-26
US11266680B2 (en) 2022-03-08
EP3082831B1 (fr) 2021-01-06
CA2930489C (fr) 2023-01-17
KR20160088874A (ko) 2016-07-26
BR112016013481A2 (pt) 2018-01-16
FR3014694B1 (fr) 2016-11-11

Similar Documents

Publication Publication Date Title
IL273090B (en) Methods and preparations for the treatment of cancer
EP3024457A4 (en) Compositions to improve the therapeutic benefit of bisantrene
IL245408B (en) Converted benzamides for the treatment of arthropods
ZA201601970B (en) Compositions useful for treating disorders related to kit
IL246252A0 (en) Diaminopyrimidyl derivative compounds, their compositions and methods of treatment
SG11201601412XA (en) Compositions and methods for the treatment of presbyopia
EP3169784A4 (en) Organic compositions to treat apoc3-related diseases
PL2984166T3 (pl) Kompozycje do leczenia mpsi
ZA201506487B (en) Therapeutic compounds and compositions
IL241264A0 (en) Compounds and compositions for the treatment of parasitic diseases
SG10201706960TA (en) Organic compositions to treat epas1-related diseases
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
SG11201505220VA (en) Prevention & treatment of neuropathy
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
EP3010504A4 (en) Methods and compositions to treat cancer
GB201607581D0 (en) Treatment of cancer
ZA201506392B (en) Compositions and methods including celecoxib and plumbagin relating to treatment of cancer
ZA201509360B (en) Compositions and methods for treatment of stroke
PL3079684T3 (pl) Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna
SG11201509640RA (en) Use of an isopropanol-containing solution to combat calciviridae
PT3041488T (pt) Composições de mel
ZA201404930B (en) Plant treatment composition
AU2013903871A0 (en) Compositions for treating skin conditions